Compoundeer Logo
COMPOUNDEER
Uncovering Potential
RankingCompaniesDCF
BLCO Logo

Bausch & Lomb Corp

BLCO

Ophthalmic Goods

Mkt Cap

$5.386B

PE

-15.98

Debt

$4.684B

Cash

$325M

EV

$9.745B

FCF

-$131M

Market Cap

$5.386B

P/E Ratio

-15.98

Debt

$4.684B

Cash

$325M

EV

$9.745B

FCF

-$131M
Charts data: {"Earnings":[{"time":"2020-12-30","value":-18000000},{"time":"2021-12-30","value":182000000},{"time":"2022-12-30","value":6000000},{"time":"2023-12-30","value":-260000000}],"Sales":[{"time":"2020-12-30","value":3412000000},{"time":"2021-12-30","value":3765000000},{"time":"2022-12-30","value":3768000000},{"time":"2023-12-30","value":4146000000}],"Net Margins":[{"time":"2020-12-30","value":-0.005275498241500586},{"time":"2021-12-30","value":0.04833997343957503},{"time":"2022-12-30","value":0.0015923566878980893},{"time":"2023-12-30","value":-0.06271104679208876}],"Assets":[{"time":"2021-12-30","value":10823000000},{"time":"2022-12-30","value":11144000000},{"time":"2023-12-30","value":13442000000}],"Stockholders Equity":[{"time":"2020-12-30","value":9988000000},{"time":"2021-12-30","value":9402000000},{"time":"2022-12-30","value":7101000000},{"time":"2023-12-30","value":6920000000}],"ROE":[{"time":"2020-12-30","value":-0.001802162595114137},{"time":"2021-12-30","value":0.019357583492873857},{"time":"2022-12-30","value":0.0008449514152936206},{"time":"2023-12-30","value":-0.03757225433526012}],"ROA":[{"time":"2021-12-30","value":0.03039822600018479},{"time":"2022-12-30","value":0.018575017946877243},{"time":"2023-12-30","value":0.009671179883945842}]}

Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products for therapeutic use, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, dry eye, and redness relief. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

Sector

  • COO Logo

    COO

  • EYE Logo

    EYE

In the chart Earnings are multiplied by this value.

Earnings Growth -96%
Earnings Stability -40%


Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12-202012-202112-202212-2023TTM
Net Margin-0.53%4.8%0.16%-6.3%-7.8%
ROA-3%1.9%0.97%1%
ROE-0.18%1.9%0.084%-3.8%-5%

What is the average Net Margin?

The average Net Margin over the past 5 years is -3.06%.

What is the trend of Net Margin?

The trend of Net Margin over the past 5 years is -6.43%.

What is the average Return on Assets (ROA)?

The average ROA over the past 5 years is +1.41%.

What is the trend of Return on Assets (ROA)?

The trend of ROA over the past 5 years is -0.89%.

What is the average Return on Equity (ROE)?

The average ROE over the past 5 years is -1.84%.

What is the trend of Return on Equity (ROE)?

The trend of ROE over the past 5 years is -3.84%.


Safety & Stabiliy

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12-202012-202112-202212-2023TTM
Debt FCF-0.0014.78-23.57-35.76
Debt Equity-0.000.350.670.70
MIN
Graham Stability----460%-460%

What is the Debt/FCF?

The Debt/FCF trailing twelve month is -35.76.

What is the trend of Debt/FCF?

The trend of Debt/FCF over the past 5 years is -38.35.

What is the Graham’s Stability?

Graham’s Stability measure stands at -4.59.


Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12-202012-2022Trend
Revenue6.7%10%-0.16%
Net Income---
Stockholders Equity-12%-2.5%1.7%
FCF---230%

What is the 5 year Revenue CAGR?

The Revenue CAGR over the past 5 years is -.

What is the trend of Revenue growth?

The trend of Revenue growth rate over the past 5 years is -0.16%.

What is the 5 year Earnings CAGR?

The Earnings CAGR over the past 5 years is -.

What is the trend of Earnings growth?

The trend of Earnings growth rate over the past 5 years is -.

What is the 5 year Equity CAGR?

The Equity CAGR over the past 5 years is -.

What is the trend of Equity growth?

The trend of Equity growth rate over the past 5 years is +1.66%.

What is the 5 year FCF CAGR?

The FCF CAGR over the past 5 years is -.

What is the trend of FCF growth?

The trend of FCF growth rate over the past 5 years is -227.79%.